Primary cutaneous B-cell lymphomas (CBCL) represent approximately 20% to 25% of all
primary cutaneous lymphomas. With the advent of the World Health Organization-European …

Primary cutaneous B-cell lymphomas are a heterogeneous group of mature B-cells
neoplasms with tropism for the skin, whose biology and clinical course differ significantly …

Objective To evaluate the results of radiotherapy in patients with primary cutaneous B-cell
lymphoma (CBCL) classified according to the criteria of the World Health Organization …

Background Intravenous rituximab is a safe and effective option for the treatment of systemic
non‐Hodgkin B‐cell lymphoma. The effectiveness of intralesional rituximab (ILR) in primary …

The choice of therapy for primary cutaneous B-cell lymphoma (PCBCL) relies on correct
histopathologic classification and the exclusion of systemic disease. In part II of this …

Background Primary cutaneous B-cell lymphoma (PCBCL) is a heterogeneous group of rare
clonal B-cell lymphoproliferative disorders with distinct clinicopathologic features from more …

OBJECTIVE: The tolerability and activity of the intralesional administration of rituximab, a
chimeric monoclonal antibody that targets the CD20 antigen, was assessed in patients with …

Background We have carried out a retrospective analysis to evaluate the therapeutic value
of the anti-CD20 antibody rituximab in 16 consecutive patients with primary cutaneous …

Primary cutaneous B-cell lymphomas (PCBCLs) represent a type of non-Hodgkin's
lymphoma (NHL) of the skin without evidence of extracutaneous involvement at the a …

Primary cutaneous marginal zone B-cell lymphoma (PCMZL) is included in the group of
extranodal marginal zone B-cell lymphoma involving mucosal sites. Many evidences …